Can New Therapies Be Trusted? An Evidence-Based Appraisal of Weight Loss, Immunotherapy, and Gene Editing

The Evidence-Based Truth About New Therapies: Potential, Limitations, and the Distance to Clinical Practice

The conclusion in one sentence

For any new therapy, the most reliable criterion is not how novel its name sounds or how elegant its mechanism appears, but whether comparative human trials have established its actual clinical benefit, safety, and appropriate patient population.（PMID: 35041506、PMID: 42139022、PMID: 42317330）

Where new therapies are most often misread

News reports about new therapies often collapse “biological plausibility,” “an effect observed in an animal or model,” “a signal in a small human study,” and “ready for routine use” into a single claim. These are, however, distinct stages of evidence. In the relevant original articles, Professor Lin repeatedly cautioned against presenting early findings as immediate therapeutic breakthroughs. This stance does not reject innovation; it asks that claims of efficacy remain proportionate to the maturity of the evidence.（PMID: 28424512、PMID: 35041506、PMID: 42139022）

A useful appraisal proceeds through a series of questions: Were the participants human? Was there a control group? Did the intervention outperform current care? Can the result be reproduced? Were risks followed adequately? Was the therapy studied actually the same product being marketed? If any essential link remains missing, the method should be described as promising or experimental, not as an established therapy.（PMID: 33073298、PMID: 35041506、PMID: 42139022）

Time-restricted eating: timing may add a benefit, but calories remain central

When total caloric intake is held constant, early time-restricted eating may produce genuine but modest benefits in fat loss and metabolism, and earlier eating schedules also appear more favorable in comparative studies. Thus, later literature has partly supported the research direction Professor Lin cited at the time.（PMID: 40298934、PMID: 41586347）

That does not mean meal timing has become a new weight-loss method superior to calorie control. The overall evidence still indicates that caloric restriction is the primary driver of weight loss, and self-selected time-restricted eating does not yield significantly greater weight loss than conventional calorie control. Professor Lin’s concern about extrapolating a small study into a miracle weight-loss cure therefore remains valid.（PMID: 40298934、PMID: 39973006）

The original article noted what appeared to be a vast numerical gap between “overweight and obesity” in Taiwan and “obesity” in Japan and Korea. ECU, however, did not identify systematic literature that could directly verify that specific cross-national comparison. Such comparisons also depend on differing indicator names and cutoffs. At present, the evidence should therefore be candidly labeled insufficient, and unmatched statistics should not be used to rank the countries.

Cancer immunotherapy: part of standard care, but not a wholesale replacement

Immune checkpoint therapies such as Pembrolizumab do benefit some patients with advanced non-small cell lung cancer. The key word is “some,” because outcomes vary with tumor characteristics, patient factors, and treatment combinations. Professor Lin did not portray it as a cure for every lung cancer, a position consistent with current evidence.（PMID: 42528479、PMID: 42317330）

Sipuleucel-T is indeed a cellular immunotherapy for metastatic castration-resistant prostate cancer, and studies support a survival benefit. The literature collected by ECU, however, is insufficient to verify the precise average extension in months stated in the original article. The treatment’s role and the direction of its benefit can be confirmed, but a more granular quantitative promise should not be reconstructed from the abstracts currently available.（PMID: 41497742、PMID: 41360427）

Immunotherapy has become standard care in specific lung-cancer settings, but this does not support the claim that it will inevitably replace chemotherapy across the board. Modern treatment still compares or combines immunotherapy with chemotherapy, and selection must reflect the patient’s and tumor’s characteristics. Professor Lin’s earlier doubts about wholesale replacement in the near term remain well founded.（PMID: 42317330）

Bacteriophages and exosomes: a plausible mechanism is not routine therapy

Bacteriophage therapy has research value for refractory infections, but expert literature continues to place it within an experimental-treatment framework. It therefore cannot justify routine clinical use in every setting. Professor Lin emphasized this boundary twice, in agreement with the literature.（PMID: 35041506）

As for whether there were absolutely no formal bacteriophage trials for prostatitis at that time, later case reports cannot retrospectively prove that no trial was underway anywhere in the world. This time-bound negative claim remains inadequately supported in ECU.（PMID: 37790805）

Exosomes can carry proteins, lipids, and nucleic acids and participate in intercellular communication. The literature supports this basic description, but “able to convey signals” does not mean that exosomes can already replace every form of cell therapy.（PMID: 42139022）

Exosomes derived from adipose stem cells, combined with fractional CO2 laser treatment, showed a signal of improvement in a small randomized split-face study of acne scars. Professor Lin described the dermatology literature as still sparse but potentially promising, faithfully reflecting the early stage of the research. Until more high-quality trials and long-term safety data become available, regenerative therapy should not be presented as broadly established.（PMID: 33073298、PMID: 42139022）

Umbilical cord plasma and rejuvenation: findings in mice cannot be transferred directly to humans

Human umbilical cord plasma and the TIMP2 enriched within it did improve hippocampal plasticity and cognitive performance in studies of aged mice. Professor Lin’s account of the original study is consistent with the literature.（PMID: 28424512）

The study did not, however, show that administering umbilical cord plasma or TIMP2 to humans can reverse aging or improve cognition, nor did it rule out the risk of other pathological changes. Professor Lin emphasized that the research had reached only mice and that effects in humans remained unknown. That is precisely the boundary needed to prevent animal research from being reported as demonstrated human efficacy.（PMID: 28424512）

CRISPR: scientific progress has produced clinical results while leaving safety questions

CRISPR-Cas9 can be guided to specific sites and edit genes, so explaining the concept as “correcting a typo in the genetic code” is reasonable. Actual editing in humans has, however, detected chromosomal translocations. The analogy must therefore not be read as a guarantee that only the target changes and nothing else does.（PMID: 24906146、PMID: 32029687）

When human trials were just beginning, Professor Lin stated that no one could guarantee success, accurately reflecting the uncertainty at the time. The literature has since been updated: approved CRISPR therapies and multiple clinical trials now exist, so clinical outcomes can no longer be described as entirely unknown. This new position arose through scientific progress; it does not mean that later achievements could have been known with certainty years earlier.（PMID: 42028170）

Roller-coaster-assisted stone passage: an intriguing model and plausible mechanism, but not an established prescription

A model study found stone passage of 4/24 from a front seat and 23/36 from a rear seat. In the rear-seat model, passage rates from the upper, middle, and lower calyces were 100%, 55.6%, and 40%, respectively. Professor Lin accurately reported the data and cautiously suggested, using language equivalent to “perhaps,” that a rear seat might help stones pass.（PMID: 27669068）

The direct evidence came from an in vitro silicone model, not a clinical trial in real roller-coaster riders. Clinical studies closer to the underlying mechanism indicate that mechanical percussion or vibration combined with positional changes may help clear renal calyceal stones, giving the idea a plausible basis. Existing evidence cannot establish whether riding a roller coaster should be used as treatment or which patients, if any, would be suitable.（PMID: 27669068、PMID: 28556853、PMID: 31062070、PMID: 38230313）

Practical guidance for readers

When encountering words such as “breakthrough,” “regenerative,” “precision,” or “immune,” first identify the research stage and the comparator. If evidence extends only to cells, animals, models, case reports, or small early trials, the most reasonable conclusion is usually that the approach deserves study—not that it should independently replace standard treatment.（PMID: 28424512、PMID: 33073298、PMID: 35041506）

Even a genuinely mature new therapy often works only for a clearly defined population and must be coordinated with existing treatments rather than eliminating every older method overnight. Remaining hopeful about innovation while verifying its claims is the durable principle of health-evidence appraisal that runs through this group of articles.（PMID: 42317330、PMID: 42028170）